RT Journal Article
SR Electronic
T1 Neutralization of SARS-CoV-2 variants by convalescent and vaccinated serum
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.04.21254881
DO 10.1101/2021.04.04.21254881
A1 Bates, Timothy A.
A1 Leier, Hans C.
A1 Lyski, Zoe L.
A1 McBride, Savannah K.
A1 Coulter, Felicity J.
A1 Weinstein, Jules B.
A1 Goodman, James R.
A1 Lu, Zhengchun
A1 Siegel, Sarah A. R.
A1 Sullivan, Peter
A1 Strnad, Matt
A1 Brunton, Amanda E.
A1 Lee, David X.
A1 Curlin, Marcel E.
A1 Messer, William B.
A1 Tafesse, Fikadu G.
YR 2021
UL http://medrxiv.org/content/early/2021/04/09/2021.04.04.21254881.abstract
AB We tested human sera from large, demographically balanced cohorts of BNT162b2 vaccine recipients (n=51) and COVID-19 patients (n=44) for neutralizing antibodies against SARS-CoV-2 variants B.1.1.7 and B.1.351. Although the effect is more pronounced in the vaccine cohort, both B.1.1.7 and B.1.351 show significantly reduced levels of neutralization by vaccinated and convalescent sera. Age is negatively correlated with neutralization in vaccinee, and levels of variant-specific RBD antibodies are proportional to neutralizing activities.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded in part by an unrestricted grant from the M.J. Murdock Charitable Trust, by NIH training grant T32AI747225 on Interactions at the Microbe-Host Interface, and OHSU Innovative IDEA grant 1018784, and NIH R01AI145835.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted in accordance with the Oregon Health & Science University Institutional Review Board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available up on request